Login to Your Account

PTC's Translarna scores NICE recommendation; full EMA nod pending

By Nuala Moran
Staff Writer

Monday, April 18, 2016

LONDON – PTC Therapeutics Inc.'s muscular dystrophy therapy Translarna has survived intense scrutiny by NICE to emerge with a recommendation that it is funded under a managed access agreement.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription